Use of sacubitril/valsartan in Marfan syndrome–related cardiomyopathy
暂无分享,去创建一个
M. Ciccozzi | S. Angeletti | S. Spoto | A. Pantano | S. Costantino | L. Locorriere | E. Valeriani | G. Anguissola | F. Terracciani | M. Bono
[1] E. Braunwald,et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.
[2] H. Yoo,et al. The phenotypic heterogeneity of patients with Marfan-related disorders and their variant spectrums , 2018, Medicine.
[3] P. Martens,et al. Insights into implementation of sacubitril/valsartan into clinical practice , 2018, ESC heart failure.
[4] K. Lindmark,et al. Eligibility of sacubitril–valsartan in a real‐world heart failure population: a community‐based single‐centre study , 2018, ESC heart failure.
[5] Peter P. Liu,et al. Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients. , 2017, American journal of cardiovascular disease.
[6] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. , 2017, JACC. Heart failure.
[7] Volkmar Falk,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.
[8] E. Wellnhofer,et al. NT-proBNP and diastolic left ventricular function in patients with Marfan syndrome , 2016, International journal of cardiology. Heart & vasculature.
[9] R. Hetzer,et al. Cardiomyopathy in Marfan syndrome. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[10] S. Solomon,et al. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. , 2015, The New England journal of medicine.
[11] P. Robinson,et al. The Application of Clinical Genetics Dovepress Perspectives on the Revised Ghent Criteria for the Diagnosis of Marfan Syndrome , 2022 .
[12] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure , 2015, Circulation.
[13] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[14] Laurence Faivre,et al. The revised Ghent nosology for the Marfan syndrome , 2010, Journal of Medical Genetics.
[15] Benjamin S. Brooke,et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. , 2008, The New England journal of medicine.
[16] J. Struck,et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. , 2005, Clinical chemistry.
[17] G. Schreiner,et al. B-Type Natriuretic Peptide Exerts Broad Functional Opposition to Transforming Growth Factor-&bgr; in Primary Human Cardiac Fibroblasts: Fibrosis, Myofibroblast Conversion, Proliferation, and Inflammation , 2004, Circulation research.
[18] Volkmar Falk,et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.